Dr. Lal Path Labs Ltd. — Results, 30-01-2025: Integrated Filing- Financial

Dr. Lal PathLabs has announced a board meeting on January 30, 2025, to review the financial results for the quarter and nine months ended December 31, 2024. The consolidated income stood at ₹6,218 million, marking a slight increase from the previous quarter, with a profit before tax of ₹1,811 million. The Board also approved a third interim dividend of ₹6 per equity share. The dissolution of its Kenyan subsidiary and the potential voluntary liquidation of Suburban Diagnostics may streamline operations. Investors might view these developments positively due to the sustained profitability and ongoing strategic consolidations.